Stock Traders Buy High Volume of Medtronic Call Options (NYSE:MDT)

Medtronic PLC (NYSE:MDT) was the target of some unusual options trading activity on Tuesday. Traders bought 19,654 call options on the stock. This represents an increase of 56% compared to the typical daily volume of 12,590 call options.

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares in the company, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.26% of the stock is currently owned by corporate insiders.

Institutional Trading of Medtronic

A number of hedge funds have recently modified their holdings of MDT. Jupiter Wealth Management LLC bought a new position in shares of Medtronic during the 2nd quarter worth approximately $469,000. Madison Asset Management LLC bought a new stake in Medtronic in the second quarter valued at $18,589,000. Flossbach Von Storch SE acquired a new position in Medtronic during the second quarter worth $85,223,000. Sound Financial Strategies Group LLC acquired a new position in Medtronic during the second quarter worth $237,000. Finally, Strategic Wealth Advisors LLC lifted its holdings in shares of Medtronic by 135.9% during the second quarter. Strategic Wealth Advisors LLC now owns 1,118 shares of the medical technology company’s stock valued at $87,000 after acquiring an additional 644 shares during the period. Institutional investors own 82.06% of the company’s stock.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: UBS upgraded Medtronic to Buy from Neutral, describing a potential turnaround underway after years of underperformance. The upgrade supports the view that new products, improving execution, and stabilizing growth could drive further gains. Is Medtronic Becoming a Turnaround Story?
• Positive Sentiment: Medtronic is positioned in the fast-growing pulsed-field ablation market, which ResearchAndMarkets projects will expand from approximately $3.2 billion in 2026 to $14.6 billion by 2035. Participation in this market could provide a meaningful long-term growth opportunity for the company’s cardiac portfolio. Pulsed Field Ablation Global Market Report 2026
• Positive Sentiment: The company continues to benefit from a solid financial profile and dividend appeal. Recent commentary characterized Medtronic as an undervalued Dividend Aristocrat, while its latest quarter included $9.81 billion in revenue, up 9.9% year over year, and EPS of $1.55 versus a $1.54 consensus estimate. Medtronic: Buy This Undervalued Dividend Aristocrat
• Neutral Sentiment: A collaboration with Orchestra BioMed remains on track. The BACKBEAT pivotal trial, conducted with Medtronic, is expected to reach its enrollment target by the end of the third quarter of 2026, with primary data targeted for the second quarter of 2027. The program could create future value, but meaningful clinical and commercial milestones remain ahead. Orchestra BioMed Reports Second Quarter 2026 Results
• Negative Sentiment: Investors remain cautious about whether Medtronic’s turnaround can deliver sustainable growth. Comparisons with faster-growing peers such as Abbott and Johnson & Johnson highlight ongoing concerns about execution, procedure volumes, and the company’s slower historical growth. The stock’s valuation and 2027 EPS guidance will likely remain under scrutiny. Abbott vs. Medtronic

Wall Street Analysts Forecast Growth

MDT has been the topic of a number of recent research reports. Needham & Company LLC restated a “buy” rating and issued a $101.00 target price on shares of Medtronic in a research note on Wednesday, June 17th. Rothschild & Co Redburn cut their price target on Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research note on Friday, June 5th. UBS Group upgraded Medtronic from a “neutral” rating to a “buy” rating and lifted their price target for the company from $85.00 to $100.00 in a report on Tuesday, July 28th. BTIG Research reissued a “buy” rating and issued a $91.00 price target on shares of Medtronic in a research note on Monday, July 13th. Finally, Truist Financial dropped their price objective on Medtronic from $95.00 to $86.00 and set a “hold” rating on the stock in a report on Thursday, June 4th. Eighteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.83.

Medtronic Stock Performance

Medtronic stock traded up $0.36 during mid-day trading on Tuesday, reaching $89.77. The company had a trading volume of 1,506,073 shares, compared to its average volume of 8,953,453. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. The firm has a market cap of $114.91 billion, a price-to-earnings ratio of 24.07, a PEG ratio of 2.34 and a beta of 0.55. The company has a 50 day moving average of $82.25 and a 200-day moving average of $86.55. Medtronic has a 52 week low of $73.31 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.01. The company had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The business’s revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, sell-side analysts expect that Medtronic will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, July 17th. Investors of record on Friday, June 26th were paid a dividend of $0.72 per share. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 annualized dividend and a yield of 3.2%. The ex-dividend date was Friday, June 26th. Medtronic’s dividend payout ratio is presently 77.21%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).